Allergan to Present New Data on Bimatoprost SR at the American Glaucoma Society Annual Meeting

Source: Allergan

Allergan will present new data, including a late-breaking abstract, for Bimatoprost SR at the American Glaucoma Society (AGS) meeting in San Francisco. The abstract, to be presented for the first time on March 16, is the initial treatment duration analysis of phase 3 clinical data for Bimatoprost SR, a first-in-class sustained-release, biodegradable implant being evaluated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension. Topline phase 3 efficacy and safety results from the ongoing studies will also be presented at a congress later this year. Allergan anticipates submitting a new drug application (NDA) to the FDA in the second half of 2019.

“This first presentation showing the treatment duration from the phase 3 studies confirms that Bimatoprost SR could represent a major paradigm shift in the management of glaucoma. Bimatoprost SR demonstrated an extended duration of effect in many patients, and the potential for most patients to need no additional treatment for one year after three administrations of the implant,” Yehia Hashad, MD, Vice President and Global Head, Clinical Development, Eye Care, Allergan, said in a company news release. “The development of Bimatoprost SR demonstrates our continued commitment to developing innovative therapies for glaucoma, a progressive disease that requires consistent IOP control to preserve vision for patients.”

Allergan will present two abstracts, including one podium presentation (accepted as a late- breaking abstract) and one poster presentation (all noted in local Pacific Standard Time):

  • AGS Poster Session (Friday, March 15, 7:00 AM – 5:00 PM):
    Logistic Regression Analysis of Baseline Patient Characteristics Predicting IOP Control Up to 24 Months After a Single Administration of Bimatoprost SR

    • Author: AhmedIIKetal, et al.


  • AGS Podium Session (Saturday, March 16, 4:35 PM): Extended Duration of IOP Control with Intracameral Bimatoprost Sustained-Release Implant (Bim SR): Late-Breaking Phase 3 Clinical Trial Results
    • Author: AhmedIIKetal, et al.
    • Time:4:35PM

Related Content